positive
7h agoTorrent Pharma posts 30% jump in Q2 profit driven by strong India sales

Torrent Pharmaceuticals reported a 30% year-on-year increase in consolidated Q2 net profit to ₹591 crore, supported by robust domestic and US market performance. Revenue improved due to healthy growth in key therapeutic segments and margin expansion. Management attributed the strong results to portfolio optimization and improved operating efficiency.
The company also highlighted ongoing capacity expansion and new product launches planned for FY26. Following the announcement, Torrent’s shares gained in early trade amid positive investor sentiment on its sustained growth outlook.
Explore:Mutual Fund Categories
positive
7h agoTorrent Pharma posts 30% jump in Q2 profit driven by strong India sales

Torrent Pharmaceuticals reported a 30% year-on-year increase in consolidated Q2 net profit to ₹591 crore, supported by robust domestic and US market performance. Revenue improved due to healthy growth in key therapeutic segments and margin expansion. Management attributed the strong results to portfolio optimization and improved operating efficiency.
The company also highlighted ongoing capacity expansion and new product launches planned for FY26. Following the announcement, Torrent’s shares gained in early trade amid positive investor sentiment on its sustained growth outlook.
Explore:Mutual Fund Categories
about 7 hours ago
1 min read
79 words

Torrent Pharmaceuticals’ Q2 profit rose 30% YoY to ₹591 crore, driven by strong India and US markets, margin gains, and upcoming new product launches boosting investor sentiment.
Torrent Pharmaceuticals reported a 30% year-on-year increase in consolidated Q2 net profit to ₹591 crore, supported by robust domestic and US market performance. Revenue improved due to healthy growth in key therapeutic segments and margin expansion. Management attributed the strong results to portfolio optimization and improved operating efficiency.
The company also highlighted ongoing capacity expansion and new product launches planned for FY26. Following the announcement, Torrent’s shares gained in early trade amid positive investor sentiment on its sustained growth outlook.

Torrent Pharmaceuticals reported a 30% year-on-year increase in consolidated Q2 net profit to ₹591 crore, supported by robust domestic and US market performance. Revenue improved due to healthy growth in key therapeutic segments and margin expansion. Management attributed the strong results to portfolio optimization and improved operating efficiency.
The company also highlighted ongoing capacity expansion and new product launches planned for FY26. Following the announcement, Torrent’s shares gained in early trade amid positive investor sentiment on its sustained growth outlook.
Companies:
Torrent Pharmaceuticals
Tags:
stocks
torrent pharma
stocks
torrent pharma
earnings
pharma sector
profits
Nov 8, 2025 • 05:04 IST